IPO or merger? Kiran Mazumdar-Shaw weighs $4.5-billion Biocon Biologics move

Biocon's founder and chairperson Kiran Mazumdar-Shaw has appointed Morgan Stanley to arrive at a decision for a Biocon Biologics IPO or merger.

Business